Impact of the Covid-19 pandemic on lung cancer treatment and research
Impact of the Covid-19 pandemic on lung cancer treatment and research
Despite recent advances in immunotherapy and targeted therapy, the mortality rate seen in lung cancer (LC) is the highest of all cancer forms. The recent topical coronavirus disease 19 (COVID-19) and its subsequent pandemic have resulted in over 505 million confirmed cases and approximately 6.2 million fatalities as of April 2022 (1), with a staggering 30%–50% mortality rate seen in LC patients with COVID-19 (2). Cancer patients, in particular, are highly vulnerable to COVID-19 infection due to immunosuppression, from both the tumor and its treatments. Here we report the impact of the pandemic to be largely negative on LC treatment and research
Lovlekar, Shreya Kailas
a27afe1d-45d8-40a8-b00f-4a6d3c0ef1fd
Wang, Yihua
f5044a95-60a7-42d2-87d6-5f1f789e3a7e
24 March 2023
Lovlekar, Shreya Kailas
a27afe1d-45d8-40a8-b00f-4a6d3c0ef1fd
Wang, Yihua
f5044a95-60a7-42d2-87d6-5f1f789e3a7e
Lovlekar, Shreya Kailas and Wang, Yihua
(2023)
Impact of the Covid-19 pandemic on lung cancer treatment and research.
Genes and Diseases.
Abstract
Despite recent advances in immunotherapy and targeted therapy, the mortality rate seen in lung cancer (LC) is the highest of all cancer forms. The recent topical coronavirus disease 19 (COVID-19) and its subsequent pandemic have resulted in over 505 million confirmed cases and approximately 6.2 million fatalities as of April 2022 (1), with a staggering 30%–50% mortality rate seen in LC patients with COVID-19 (2). Cancer patients, in particular, are highly vulnerable to COVID-19 infection due to immunosuppression, from both the tumor and its treatments. Here we report the impact of the pandemic to be largely negative on LC treatment and research
Text
GenDis_Rapid Comm_R1
- Accepted Manuscript
More information
Accepted/In Press date: 29 January 2023
e-pub ahead of print date: 24 March 2023
Published date: 24 March 2023
Additional Information:
Funding: YW was supported by the Medical Research Council (UK) (No. MR/S025480/1) and an Academy of Medical Sciences/the Wellcome Trust Springboard Award (UK) (No. 100 SBF002\1038). For the purpose of open access, the authors have applied a CC-BY public copyright license to any Author Accepted Manuscript version arising from this submission.
Identifiers
Local EPrints ID: 475011
URI: http://eprints.soton.ac.uk/id/eprint/475011
ISSN: 2352-3042
PURE UUID: 458e9069-d90e-488e-a854-809ed0b1d084
Catalogue record
Date deposited: 08 Mar 2023 17:54
Last modified: 17 Mar 2024 03:39
Export record
Contributors
Author:
Shreya Kailas Lovlekar
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
